Home Biosimilar Antibodies Apoptosis TNF-alpha Certolizumab (Anti-TNFSF2 / TNFa)
For research use only. Not for use in humans.

Certolizumab (Anti-TNFSF2 / TNFa)

Synonyms: Tnf,TNF alpha

Certolizumab (anti-TNFSF2 / TNFa) is a Fab fragment of a recombinant, humanized monoclonal antibody directed against the proinflammatory cytokine tumor necrosis factor-alpha (TNF-alpha) with anti-inflammatory activity. MW: 144.92 kD.

Certolizumab (Anti-TNFSF2 / TNFa)

Quality Control

Batch: A279801 Purity: 99% Protein concentration: 5.09mg/ml Endotoxin Level: ＜1EU/mg
99

Specificity

Name Citation TNF-α TNF-alpha Others
QNZ (EVP4593) 156 NF-κB
JTE-607 Dihydrochloride 2 IL-1beta,IL-8,IL-6
PF-3644022 2 MK2
UCB-9260 0 NF-κB
MD2-TLR4-IN-1 2 TLR4,IL-6
R-7050 11 IL-1β
Resatorvid (TAK-242) 65 TLR4,IL-6,NO
Apigenin-7-O-glucuronide 0
UTL-5g 0
Benpyrine racemate 1
Amarogentin 0 TAS2R1,AMPK
Stylopine 0 IL-1β,NO,COX-2
Myrislignan 1 iNOS,IL-6,NF-κB
NE 52-QQ57 2 iNOS,IL-6,IL-1β
(3R,8S)-Falcarindiol 3 IL-1β,IL-6,iNOS
Gardenoside 1 NF-κB,P2X7 Receptor,IL-6
Cucurbitacin IIb 1 JNK,STAT3,NF-κB
IQ 3 1 IL-6,JNK3,JNK1
Isuzinaxib (APX-115 free base) 2 IL-6,MCP-1/CCL2,NOX2
AUDA 1 Smad3,TGF-β,IL-1β
CPI-1189 1
Madecassic acid 3 IL-1β,COX-2,iNOS
Homoplantaginin 1 IL-6,IKKβ,NF-κB
2',5'-Dihydroxyacetophenone 1 IL-6,NF-κB,ERK1/2
Forsythoside B 0 IκB,NF-κB,IL-6
Mulberroside A 0 ERK,NF-κB,Caspase-1
Ginsenoside Rb1 4 TLR3,NF-κB,IRAK-1
Muscone 4 IL-6,IL-1β,NLRP3 inflammasome
(Rac)-Shikonin 44 NF-κB,Proteasome,chemokine receptor
Methylthiouracil 1 IL-6,ERK1/2,NF-κB
Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Certolizumab (anti-TNFSF2 / TNFa) is a Fab fragment of a recombinant, humanized monoclonal antibody directed against the proinflammatory cytokine tumor necrosis factor-alpha (TNF-alpha) with anti-inflammatory activity. MW: 144.92 kD.
References

Product Details

CAS No. 428863-50-7
Molecular Weight 144.92
Isotype Human IgG1
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT07352566 NOT_YET_RECRUITING Drug: Triamcinolone|Drug: 5-Fluorouracil|Drug: Calcipotriene Psoriasis; Atopic Dermatitis University of California, San Francisco 2026-08-01 PHASE4
NCT05930613 RECRUITING Drug: Certolizumab (CIMZIA® ; TNF-α antagonist)|Drug: Placeb Recurrent Unexplained Implantation Failure Assistance Publique - Hôpitaux de Paris 2023-11-30 PHASE3
NCT03546335 SUSPENDED Drug: 89Zr-DFO-CZP Rheumatoid Arthritis Robert Flavell, MD, PhD 2018-10-01 PHASE1
NCT03414502 RECRUITING Drug: Methotrexate|Drug: Abatacept|Drug: Adalimumab|Drug: Az Rheumatoid Arthritis University of Nebraska 2007-12-10 PHASE3
NCT07138898 RECRUITING Drug: Methotrexate|Drug: Sulfasalazine|Drug: Hydroxychloroqu Rheumatic Disease NYU Langone Health 2025-12-12 PHASE2
NCT07491913 RECRUITING Drug: Tociliuzumab|Drug: Infliximab|Drug: Adalimumab|Drug: C Takayasu Arteritis Marmara University 2025-06-15

(data from https://clinicaltrials.gov, updated on 2026-06-03)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.